UPGOLYV DIN 02567423
Status: Approved
Holder: JAMP PHARMA CORPORATION
Health Canada record
| Active ingredient(s) | GOLIMUMAB 50 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AB06 GOLIMUMAB |
|---|
| Original market date | |
|---|
| Current status date | 10-Apr-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GOLIMUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02559560 | LIVMOTY | JANSSEN INC | Solution | GOLIMUMAB 50 MG | Approved |
| 02559536 | LIVMOTY | JANSSEN INC | Solution | GOLIMUMAB 100 MG | Approved |
| 02559544 | LIVMOTY | JANSSEN INC | Solution | GOLIMUMAB 100 MG | Approved |
| 02559552 | LIVMOTY | JANSSEN INC | Solution | GOLIMUMAB 50 MG | Approved |
| 02324776 | SIMPONI | JANSSEN INC | Solution | GOLIMUMAB 50 MG | Marketed |
| 02324784 | SIMPONI | JANSSEN INC | Solution | GOLIMUMAB 50 MG | Marketed |
| 02413175 | SIMPONI | JANSSEN INC | Solution | GOLIMUMAB 100 MG | Marketed |
| 02413183 | SIMPONI | JANSSEN INC | Solution | GOLIMUMAB 100 MG | Marketed |
| 02417472 | SIMPONI I.V. | JANSSEN INC | Solution | GOLIMUMAB 50 MG | Marketed |
| 02567393 | UPGOLYV | JAMP PHARMA CORPORATION | Solution | GOLIMUMAB 50 MG | Approved |
| 02567407 | UPGOLYV | JAMP PHARMA CORPORATION | Solution | GOLIMUMAB 100 MG | Approved |
| 02567415 | UPGOLYV | JAMP PHARMA CORPORATION | Solution | GOLIMUMAB 100 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37311 | 2026-04-10 | New Drug Submission (NDS) | |
Request a quote for UPGOLYV
How to read a Canadian DIN record